Jérôme van Biervliet

Director/Miembro de la Junta en Exevir Bio BV .

Health Technology

Health Services

Perfil

Jérôme van Biervliet currently works at Waaroost NV, as Director from 2009, Augustine Therapeutics NV, as Director, and Exevir Bio BV, as Director.

Cargos activos de Jérôme van Biervliet

Empresas	Cargo	Inicio
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Director/Miembro de la Junta	-
Waaroost NV	Director/Miembro de la Junta	20/02/2009
Augustine Therapeutics NV Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.	Director/Miembro de la Junta	-

Todos los cargos activos de Jérôme van Biervliet

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Jérôme van Biervliet.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	3
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Health Technology
Waaroost NV
Augustine Therapeutics NV Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.	Health Services

Ver las conexiones de la empresa